Quantum Cyber N.V. 8K

Quantum Cyber N.V. furnished an investor presentation outlining its transition into a combat‑validated autonomous defense platform with new patent and IP licenses, U.S. Army and SOCOM‑linked commercialization efforts, and the July 15, 2026 acquisition of a Bridgeport, CT manufacturing facility to establish NDAA‑compliant domestic production capacity, alongside recent capital structure changes including debt retirement and ATM termination.

Quantum Cyber N.V. (Nasdaq: QUCY), formerly Mainz Biomed N.V., furnished an investor presentation dated July 2026 describing its strategic pivot to an autonomous defense platform, highlighting combat-tested Ukrainian and Israeli engineering, a tri‑domain AI autonomy stack (air, ground, maritime), a portfolio of eight filed patent positions plus an exclusive worldwide license to quantum photonic array technology (Project LightShift) signed June 11, 2026, and contract‑ready flagship drone platforms under letters of intent with General Cherry and SOCOM routed through its Nevada subsidiary Quantum Drones Corp. The presentation also discloses closure of a ~$2.3 million acquisition on July 15, 2026 of a ~50,000 sq ft industrial manufacturing facility at 38 Union Avenue, Bridgeport, Connecticut (with approximately $2.09 million of legacy purchase orders assumed), intended to serve as an NDAA‑compliant domestic production base capable of scaling to a targeted capacity of up to 100,000 drones per year, and outlines recent capital structure actions including raising about $15 million via warrant exercises, retiring all debt, terminating an at‑the‑market facility on June 12, 2026, and increasing basic shares outstanding to approximately 27.64 million as of July 2026 with CEO insider investment via convertible preferred stock.

Filing Facts

CIK

1874252

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-081116

Alert Tier

7